Crohn's Disease Treatment Market : Global Industry Analysis and Forecast 2016 - 2022


  • To Be Published : Feb-2017 |
  • Status : Work in progress |
  • Format :

Over the past few years, there has been a change in daily routine of population, leading to sedentary lifestyle. This has led to increasing dependency on junk foods which in turn, has led to increase in health related problems. One such common prevalent issues deals with inflammatory bowel disease (IBD) in which some parts of digestive system get swollen which is terms known as crohn’s disease. The causes of crohn’s disease may be genetics, abnormality in immune system, smoking and various other environmental factors.

This disease can develop anywhere in digestive tract, but mostly it is found in intestine. There are millions of people in the U.S. suffering from inflammatory bowel disease and thousands of new cases are diagnosed yearly, in which most of them are below the age group of 35. Also, increase in the prevalence rate of inflammatory bowel disease in developed countries, where rate of IBD occurrence is nearly 200 in every 100,000 people every year, creates good opportunities for pharmaceutical industries dealing in this market.

Factors such as increasing geriatric population and healthcare expenditure, increasing awareness among the teenagers and the various treatments options are expected to drive the crohn’s disease treatment market over the forecast period. Also, increasing number of smokers is driving the crohn’s disease treatment market as they are more likely to develop crohn’s disease. However, complications, side effects of medication and negative response to previous medication is likely to restraint the growth of crohn’s disease treatment market.

Crohn's disease treatment market is classified on the basis of drug type and distribution.

Crohn's disease treatment By Product

  • Anti-inflammatory drugs
  • Immune system suppressors
  • Antibiotics
  • Other medications

Crohn's disease treatment By Distribution,

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Retail Pharmacies

Crohn’s disease treatment market is expected to grow at a healthy CAGR during the forecast period. Also, countries in Western European region have high prevalence of crohn’s disease as compared to Asia Pacific region. Crohn’s disease treatment market in North America and Western European countries is growing with a significant CAGR compared to rest of the world.

Depending on geographic region, crohn’s disease treatment market is segmented into seven key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America held largest share in the global market of crohn’s disease treatment market followed by Europe, Asia Pacific owing to high occurrence of several crohn’s diseases and disorders, great advancement in field of technology and developed healthcare infrastructure. The developing nations in Asia Pacific, Middle East and Africa hold huge potential for growth in the crohn’s disease market, due to untapped market and unavailability of various drugs and treatments in these region.

Some of the key participating global players in crohn’s disease treatment market are AbbVie Inc., Pfizer, Johnson & Johnson, Abbott, and AstraZeneca.

 The report covers exhaustive analysis on:

  • Crohn's Disease Treatment Market Segments
  • Crohn's Disease Treatment Market Dynamics
  • Historical Actual Market Size, 2013 - 2015
  • Crohn's Disease Treatment Market Size & Forecast 2016 to 2022
  • Crohn's Disease Treatment Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Crohn's Disease Treatment Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance
Back To Top